Table 3.
Therapy after admission of the lowest and highest HbA1c groups
| Therapy after admission | Lowest (%) | Highest (%) | Total number | |
|---|---|---|---|---|
| Lowest | Highest | |||
| Thrombosis (%), studies = 3 | 7.40 | 11.86 | 36,328 | 6808 |
| PCI (%), studies = 13 | 94.86 | 88.92 | 42,985 | 9124 |
| PCI (successful) (%), studies = 6 | 92.99 | 90.05 | 5477 | 3114 |
| CABG (%), studies = 3 | 19.90 | 16.44 | 39,291 | 6326 |
| Antiplatelet agent (%), studies = 4 | 78.44 | 84.25 | 4058 | 584 |
| Aspirin (%), studies = 3 | 98.46 | 97.88 | 36,565 | 6925 |
| Clopidogrel or Tigrilo (%), studies = 3 | 72.32 | 69.16 | 36,565 | 6925 |
| Lipid lowering drugs (%), studies = 7 | 92.74 | 89.93 | 40,623 | 7509 |
| Beta blockers (%), studies = 7 | 94.79 | 90.98 | 40,623 | 7509 |
| ACEI/ARB (%), studies = 7 | 73.92 | 77.34 | 40,623 | 7509 |
PCI percutaneous coronary intervention, CABG coronary artery bypass grafting, ACEI angiotensin-converting enzyme inhibitors, ARB angiotensin receptor blocker